FDA approves nasal spray for kids ages 2 to 5

Article

The U.S. Food and Drug Administration (FDA) has approved triamcinolone acetonide for sneezing, runny nose, and congestion caused by allergic rhinitis in pre-schoolers, according to the manufacturer Sanofi-aventis.

The U.S. Food and Drug Administration (FDA) has approved triamcinolone acetonide for sneezing, runny nose, and congestion caused by allergic rhinitis in pre-schoolers, according to the manufacturer Sanofi-aventis.

The nasal spray, called Nasacort AQ, was tested in a randomized, double-blind, placeb-controlled trial of 464 children with allergic rhinitis. One spray per nostril daily for four weeks showed that while the instantaneous reduction in the primary endpoint, Total Nasal Symptom Score (TNSS), was not significant, triamcinolone did significantly reduce TNSS at 24 hours.

In addition, 50.8% of participants receiving treatment and 48.3% of participants receiving placebo experienced adverse events, the most common of which was cough (cough rates: 7.6% in treatment group, 9.2% in placebo), followed by pyrexia and headache.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
© 2025 MJH Life Sciences

All rights reserved.